“Brutons Tyrosine Kinase (BTK) Inhibitors -Pipeline Insights, 2015”- A DelveInsight’s Report

DWARKA, India - Oct. 15, 2015 - PRLog -- The Brutons Tyrosine Kinase (BTK) Inhibitors -Pipeline Insights, 2015 reports provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:

·   33+ pipeline drugs with 20+ companies actively involved in drug development. There is 1 drug in phase III, 2 in phase II, 7 in phase I, 17 in pre-clinical, 3 in discovery, 1 in inactive and 2 in discontinued.

·    Abbvie Inc, developing a lead productIbrutinibwhichis in Phase III.

·  R&D activities and technologies used along with the pipeline molecules in development.

·  Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.

·    Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, BTK Inhibitors - Pipeline Insights, 2015 report provides the in-depth analysis of BTK Inhibitors Landscape across the globe. Therefore the report on BTK Inhibitors - Pipeline Insights provides information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveInsight.com

About Us

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.